Breaking News

Theravectys Opens New Facility

Granted authorization to produce lentiviral vectors for clinical use and CAR-T cell therapies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Theravectys, a clinical development biotechnology company that focuses on the development of therapeutic vaccines and immunotherapies, said that its manufacturing plant has obtained the status of a pharmaceutical manufacturing establishment, granted by the French National Agency for Medicines and Health Products Safety (ANSM). The new facility will be used to produce lentiviral vectors for clinical development purposes, from phase I through phase III, and will also be used to manipulate human ce...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters